Difference between revisions of "Ramosetron (Iribo)"
Jump to navigation
Jump to search
(Created page with "==Mechanism of action== Serotonin 5HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. ==History of FDA approval== Not FDA-approved; avail...") |
Warner-admin (talk | contribs) m (Text replacement - "5HT3" to "5-HT3") |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | Serotonin | + | Serotonin 5-HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. |
==History of FDA approval== | ==History of FDA approval== | ||
Revision as of 03:25, 18 November 2017
Mechanism of action
Serotonin 5-HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties.
History of FDA approval
Not FDA-approved; available in Japan and Southeast Asia.
Also known as
IBset, Nasea, Nozia